nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.03.2009 | Editorial

Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma

verfasst von: Frederik A. Verburg, Markus Dietlein, Michael Lassmann, Markus Luster, Christoph Reiners

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Excerpt

Recently an editorial by Hay et al. was published in the Journal of Nuclear Medicine favouring abolishing the use of postoperative radioiodine ablation of thyroid remnant tissue (RRA) in what they called ‘stage I’ patients [1]. In our opinion the arguments of our distinguished colleagues throw out the baby with the bathwater. In this article we outline a compelling case for the current practice of applying RRA in most patients when regarding the available evidence from another angle. …

Hay ID, McDougall IR, Sisson JC. Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J Nucl Med 2008;49:1395–7.CrossRef

Sawka AM, Goldstein DP, Thabane L, Brierley JD, Tsang RW, Rotstein L, et al. Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. Endocr Pract 2008;14:175–84.PubMed

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109–42.PubMed

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.PubMedCrossRef

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941–59.PubMedCrossRef

Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 2007;46:213–9.PubMed

Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007;46:206–12.PubMed

Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297–306.PubMedCrossRef

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–28.PubMedCrossRef

10.

Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.PubMedCrossRef

11.

Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794–804.PubMedCrossRef

12.

Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:1063–75.PubMed

13.

Utiger RD. Follow-up of patients with thyroid carcinoma. N Engl J Med 1997;337:928–30.PubMedCrossRef

14.

Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629–34.PubMedCrossRef

15.

Tenenbaum F, Corone C, Schlumberger M, Parmentier C. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer 1996;32A:1262.PubMedCrossRef

16.

Travagli JP, Cailleux AF, Ricard M, Baudin E, Parmentier C, Schlumberger M, et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 1998;83:2675–80.PubMedCrossRef

17.

Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229–42.PubMedCrossRef

18.

Machens A, Holzhusen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative analysis. Cancer 2005;103:2269–73.PubMedCrossRef

19.

Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457–80.PubMedCrossRef

20.

Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005;352:2406–12.PubMedCrossRef

21.

Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005;153:651–9.PubMedCrossRef

22.

Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105–12.PubMedCrossRef

23.

Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005;152:33–7.PubMedCrossRef

24.

Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088–95.PubMed

25.

Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma. Surgery 1998;124:958–64.PubMed

26.

Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular carcinoma. J Surg Oncol 2006;94:692–700.PubMedCrossRef

27.

Hölzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, et al. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer 2000;89:192–201.PubMedCrossRef

28.

Solans R, Bosch JA, Galofre P, Porta F, Roselló J, Selva-O’Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738–43.PubMed

29.

Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49:546–9.PubMedCrossRef

30.

Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87:5817–20.PubMedCrossRef

31.

Seidlin SM, Siegal E, Yalow AA, Melamed S. Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma. Science 1956;123:800–1.PubMedCrossRef

32.

Seidlin SM, Siegel E, Melamed S, Yalow AA. Occurrence of myeloid leukemia in patients with metastatic thyroid carcinoma following prolonged massive radioiodine therapy. Bull N Y Acad Med 1955;31:410.PubMed

33.

Seidlin SM, Yalow AA, Siegel E. Blood radiation dose during radioiodine therapy of metastatic thyroid carcinoma. Radiology 1954;63:797–813.PubMed

34.

Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005;117:281–8.PubMedCrossRef

35.

Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504–15.PubMedCrossRef

36.

Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638–44.PubMedCrossRef

37.

Verkooijen RB, Smit JW, Romijn JA, Stokkel MP. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 2006;155:801–6.PubMedCrossRef

38.

Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 2006;115:607–10.PubMed

39.

Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648–54.PubMed

40.

Leeper RD. The effect of 131I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 1973;36:1143–52.PubMedCrossRef

41.

Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405–12.PubMedCrossRef

42.

Dragoiescu C, Hoekstra OS, Kuik DJ, Lips P, Plaizier MA, Rodrigus PT, et al. Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. Clin Endocrinol 2003;58:451–5.CrossRef

Titel: Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
verfasst von: Frederik A. Verburg
Markus Dietlein
Michael Lassmann
Markus Luster
Christoph Reiners
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0997-5

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT

Metabolic–flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT

Ich bin ein Molekularmediziner (how much CT and nuclear medicine in molecular CT?)

Effects of long-term practice and task complexity on brain activities when performing abacus-based mental calculations: a PET study

Hybrid PET-dynamic CECT in the management of breast cancer

Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET